Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

NCT03408899 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: PC-1005 gel

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)